Pharmaron Beijing Co., Ltd. disclosed a transfer of 5.40 million treasury H shares on 22 July 2026. The shares were moved to the company’s trustee to facilitate the vesting of awards under the 2025 H Share Award and Trust Scheme.

• Capital structure impact – Issued H shares (excluding treasury) rose 1.53% to 358.11 million from 352.71 million. – Treasury share balance fell to 1.87 million from 7.26 million. – Total issued shares remained unchanged at 359.98 million, indicating no new shares were created; existing treasury shares were re-designated for employee incentives.

• Pricing – The transfer was executed at HKD0 per share as it involved an internal reallocation rather than an on-market sale.

The company secretary confirmed the transaction was authorised by the board and complies with Hong Kong Listing Rules and all relevant regulatory requirements.